(R)-4-Methyloxazolidin-2-one → (R)-3-{5-[4-(4-chlorobenzoyl)piperidine-1-carbonyl]pyridin-2-yl}-4-methyloxazolidin-2-one

HRID 1803969

反応式

HRID 1803969 の反応式
Br[C:2]1[N:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][CH:13]([C:16](=[O:24])[C:17]3[CH:22]=[CH:21][C:20]([Cl:23])=[CH:19][CH:18]=3)[CH2:12][CH2:11]2)=[O:9])=[CH:4][CH:3]=1.[CH3:25][C@@H:26]1[CH2:30][O:29][C:28](=[O:31])[NH:27]1>>[Cl:23][C:20]1[CH:21]=[CH:22][C:17]([C:16]([CH:13]2[CH2:14][CH2:15][N:10]([C:8]([C:5]3[CH:4]=[CH:3][C:2]([N:27]4[C@H:26]([CH3:25])[CH2:30][O:29][C:28]4=[O:31])=[N:7][CH:6]=3)=[O:9])[CH2:11][CH2:12]2)=[O:24])=[CH:18][CH:19]=1

参加物

3

反応物 2

HCID 2734858(R)-4-Methyloxazolidin-2-oneHCID 58484839(6-Bromopyridin-3-yl)[4-(4-chlorobenzoyl)piperidin-1-yl]methanone

生成物 1

HCID 54755117(R)-3-{5-[4-(4-chlorobenzoyl)piperidine-1-carbonyl]pyridin-2-yl}-4-methyloxazolidin-2-one収率 41.8%

実験手順

By reaction and treatment in the same manner as in Preparation Example 31 and using (6-bromopyridin-3-yl)[4-(4-chlorobenzoyl)piperidin-1-yl]methanone (2 g) described in Preparation Example 23 and (R)-4-methyloxazolidin-2-one (288 mg) described in Preparation Example 25, the title compound (510 mg) was obtained.

後処理

  1. customBy reaction and treatment in the same manner
  2. customas in Preparation Example 31
  3. customdescribed in Preparation Example 25

出典と根拠

ORDレコード
ord-d93e8706497c4c05b6903add2c842b7b
出典データセット
uspto-grants-2013_01
特許番号
US08354401B2

関連ノート

読み込み中…